[go: up one dir, main page]

PL2601214T3 - Kompozycje antagonistyczne wobec VEGF oraz ich zastosowania - Google Patents

Kompozycje antagonistyczne wobec VEGF oraz ich zastosowania

Info

Publication number
PL2601214T3
PL2601214T3 PL11745870T PL11745870T PL2601214T3 PL 2601214 T3 PL2601214 T3 PL 2601214T3 PL 11745870 T PL11745870 T PL 11745870T PL 11745870 T PL11745870 T PL 11745870T PL 2601214 T3 PL2601214 T3 PL 2601214T3
Authority
PL
Poland
Prior art keywords
vegf antagonist
antagonist compositions
compositions
vegf
antagonist
Prior art date
Application number
PL11745870T
Other languages
English (en)
Inventor
James Stefano
Clark Pan
Huawei Qiu
Michael O'callaghan
Gloria Matthews
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of PL2601214T3 publication Critical patent/PL2601214T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL11745870T 2010-08-06 2011-08-05 Kompozycje antagonistyczne wobec VEGF oraz ich zastosowania PL2601214T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37154610P 2010-08-06 2010-08-06
EP11745870.3A EP2601214B1 (en) 2010-08-06 2011-08-05 Vegf antagonist compositions and uses thereof
PCT/US2011/046802 WO2012019128A1 (en) 2010-08-06 2011-08-05 Vegf antagonist compositions and uses thereof

Publications (1)

Publication Number Publication Date
PL2601214T3 true PL2601214T3 (pl) 2018-05-30

Family

ID=44630479

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11745870T PL2601214T3 (pl) 2010-08-06 2011-08-05 Kompozycje antagonistyczne wobec VEGF oraz ich zastosowania

Country Status (12)

Country Link
US (2) US9441029B2 (pl)
EP (2) EP3327032A1 (pl)
CY (1) CY1121111T1 (pl)
DK (1) DK2601214T3 (pl)
ES (1) ES2652508T3 (pl)
HR (1) HRP20180154T1 (pl)
HU (1) HUE035554T2 (pl)
LT (1) LT2601214T (pl)
PL (1) PL2601214T3 (pl)
PT (1) PT2601214T (pl)
SI (1) SI2601214T1 (pl)
WO (1) WO2012019128A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3005391A1 (en) * 2015-11-19 2017-05-26 Zhuhai Tairuishang Biopharm Ltd. Methods and compositions for binding vegf
CN116059318A (zh) 2018-01-26 2023-05-05 加利福尼亚大学董事会 用于使用抗vegf剂治疗血管生成病症的方法和组合物
KR20220104756A (ko) 2019-11-25 2022-07-26 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 안구내 신생혈관형성을 위한 장기지속형 vegf 억제제
EP4146686A2 (en) 2020-05-08 2023-03-15 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
DE721983T1 (de) 1988-01-22 2002-07-04 Zymogenetics, Inc. Verfahren zur herstellung von biologisch-aktive Dimerpeptiden
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
JPH03233530A (ja) 1990-02-09 1991-10-17 Fuji Photo Optical Co Ltd カメラ
US20020032313A1 (en) 1991-03-29 2002-03-14 Genentech, Inc. Vascular endothelial cell growth factor antagonists
DE69233803D1 (de) 1992-10-28 2011-03-31 Genentech Inc Verwendung von vaskulären Endothelwachstumsfaktor-Antagonisten
FR2702152B1 (fr) 1993-03-03 1995-05-24 Inst Nat Sante Rech Med Virus recombinants et leur utilisation en thérapie génique.
DE69434115T2 (de) 1993-03-25 2005-10-27 Merck & Co., Inc. Inhibitor des wachstumsfaktors für gefässendothelzellen
US6686200B1 (en) 1993-08-31 2004-02-03 Uab Research Foundation Methods and compositions for the large scale production of recombinant adeno-associated virus
US5827702A (en) 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
JPH09154588A (ja) 1995-10-07 1997-06-17 Toagosei Co Ltd Ｖｅｇｆ結合性ポリペプチド
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
CA2266419A1 (en) 1996-09-24 1998-04-02 Merck & Co., Inc. Gene therapy for inhibition of angiogenesis
JP3837748B2 (ja) 1997-01-17 2006-10-25 東亞合成株式会社 Ｖｅｇｆ結合性ポリペプチド
EP1173191A4 (en) 1997-05-13 2004-12-01 Univ California NEW ANTIANGIOGENIC PEPTIDAGENTS AND THEIR THERAPEUTIC AND DIAGNOSTIC USE
AU8435698A (en) 1997-06-03 1998-12-21 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Regulatory sequences capable of conferring expression of a heterologous dna sequence in endothelial cells in vivo and uses thereof
US6204011B1 (en) 1997-06-18 2001-03-20 Merck & Co., Inc. Human receptor tyrosine kinase, KDR
CA2303768C (en) 1997-09-19 2009-11-24 The Trustees Of The University Of Pennsylvania Methods and vector constructs useful for production of recombinant aav
US6378526B1 (en) 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
US7083950B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
WO2000054813A2 (en) 1999-03-15 2000-09-21 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
EP1183353B1 (en) 1999-06-08 2005-04-13 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US6821775B1 (en) 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
WO2002024234A2 (en) 2000-09-20 2002-03-28 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
EP1349574A2 (en) 2001-01-09 2003-10-08 MERCK PATENT GmbH Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
US20060193830A1 (en) 2002-03-20 2006-08-31 Hauswirth William W Raav vector compositions and methods for the treatment of choroidal neovascularization
CU23178A1 (es) 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
DE60336555D1 (de) 2002-06-21 2011-05-12 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
AU2004224123A1 (en) 2003-03-26 2004-10-07 Apogenix Gmbh Treatment of viral infections
US20060198819A1 (en) 2003-08-08 2006-09-07 Novo Nordisk Healthcare A/G Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
DK1804835T3 (da) * 2004-09-13 2010-10-11 Genzyme Corp Multimere konstruktioner
KR20070086218A (ko) 2004-12-17 2007-08-27 제넨테크, 인크. 자가면역 질환에 대한 이전 요법에 실패했던 환자에서의,자가면역 질환의 항-혈관신생 요법
WO2010019263A2 (en) * 2008-08-15 2010-02-18 Genzyme Corporation Soluble flt constructs for treating cancers

Also Published As

Publication number Publication date
EP2601214B1 (en) 2017-11-01
CY1121111T1 (el) 2019-12-11
DK2601214T3 (en) 2018-02-05
SI2601214T1 (en) 2018-03-30
PT2601214T (pt) 2017-12-20
US9441029B2 (en) 2016-09-13
LT2601214T (lt) 2018-02-26
US10308917B2 (en) 2019-06-04
WO2012019128A1 (en) 2012-02-09
ES2652508T3 (es) 2018-02-02
HUE035554T2 (en) 2018-05-02
EP2601214A1 (en) 2013-06-12
US20160326501A1 (en) 2016-11-10
US20130324465A1 (en) 2013-12-05
EP3327032A1 (en) 2018-05-30
HRP20180154T1 (hr) 2018-03-09

Similar Documents

Publication Publication Date Title
ZA201209259B (en) Uses and compositions
IL225463A0 (en) Preparations containing a tlr agonist and uses thereof
GB201002983D0 (en) Nutritinal composition
GB201006200D0 (en) Composition
EP2552953A4 (en) FRIZZLED-BINDING SUBSTANCES AND ITS USES
GB201006096D0 (en) Novel compositions and uses thereof
PH12013500698A1 (en) Hair-mending compositions and associated methods
GB201113770D0 (en) Novel compositions and uses thereof
GB201006178D0 (en) Composition
GB2482365B (en) Toner compositions and processes
GB201018650D0 (en) Methods and compositions
EP2874641A4 (en) COMPOSITIONS INCREASING THE GLUTATHION RATE AND USES THEREOF
IL219987A0 (en) Dp2 antagonist and uses thereof
GB2483947B (en) Toner compositions and processes
ZA201206579B (en) Endoparasiticidal compositions
LT2601214T (lt) Vegf antagonistų kompozicijos ir jų panaudojimas
GB201006214D0 (en) Composition
EP2776064A4 (en) ANTAGONISTS OF PRO-VASOPRESSIN AND USES THEREOF
GB2478399B (en) Toner compositions and methods
GB201012848D0 (en) Cement-containing compositions
GB201006204D0 (en) Composition
GB201004717D0 (en) Composition
GB201005826D0 (en) New compositions and their use
GB201006182D0 (en) Composition
GB201006175D0 (en) Composition